Clinical Trials
37 trialsNCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02720068 2025-05-30
MK-4280-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT04525014 2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1 Terminated
NCT00838578 2024-04-26
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT00060567 2023-06-18
Dose-Finding Study of E7070 in Combination With Irinotecan
Eisai Inc.
Phase 1 Completed
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT03096340 2020-12-22
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Intezyne Technologies, Inc.
Phase 1 Terminated
NCT01653470 2020-01-28
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT01479465 2019-04-17
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Gilead Sciences
Phase 2 Terminated
NCT01274624 2018-12-19
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
Phase 1 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT02620423 2018-09-13
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 1 Completed
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00845039 2018-07-02
FC-4
Eli Lilly and Company
Phase 2 Terminated
NCT01520389 2018-03-21
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
Merrimack Pharmaceuticals
Phase 1 Completed
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00563316 2016-04-12
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase 1 Completed
NCT00110357 2015-12-24
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01930552 2015-01-07
A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
Sanofi
Phase 1 Completed
NCT00298675 2012-08-02
Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00057473 2011-04-14
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
Bristol-Myers Squibb
Phase 2 Completed
NCT00473616 2011-02-11
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
AstraZeneca
Phase 1 Terminated
NCT00037804 2009-08-14
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Pfizer
Phase 1 Completed